Understanding the pathophysiology of cancer-associated thrombophilia provides a rationale for more aggressive and specific anticoagulant strategies in selected patients.
No takes yet. Share an insight, caveat, or question.
Supports targeted anticoagulation in cancer; leaves open optimal regimens for prospective trials.
Falanga et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: